Q4 2026 Aethlon Medical Inc Earnings Call Transcript
Key Points
- Aethlon Medical Inc (AEMD) achieved important clinical research and intellectual property milestones during the fiscal year.
- The company successfully completed enrollment and treatment of participants in Cohort 2 of its Australian oncology trial with no safety concerns.
- Aethlon Medical Inc (AEMD) is expanding the Hemopurifier's applications into additional disease areas through preclinical research.
- The company has maintained disciplined cost control, resulting in a 21.9% reduction in operating expenses year-over-year.
- Aethlon Medical Inc (AEMD) strengthened its balance sheet by raising approximately $1.85 million in net proceeds through its at-the-market program.
- The company's cash and cash equivalents as of March 31, 2026, were approximately $5 million, which may limit long-term financial flexibility.
- Despite progress, the Hemopurifier platform is still in the early stages of clinical trials, with primary endpoints focused on safety rather than efficacy.
- The compassionate use protocol for Ebola is specific and limited to 20 patients at up to 10 centers, which may restrict broader application.
- Aethlon Medical Inc (AEMD) experienced screen failures in its oncology trial due to patients not meeting inclusion or exclusion criteria.
- The company's net loss attributable to common stockholders was $7.2 million for the fiscal year ended March 31, 2026, indicating ongoing financial challenges.
(audio in progress) and welcome to the Aethlon Medical fiscal year end March 31, 2026, financial results and corporate update conference call. (Operator Instructions) Please note this event is being recorded.
I would now like to turn the conference over to Jim Frakes, CEO and CFO of Aethlon Medical. Please go ahead.
Thank you, operator, and good afternoon, everyone. Welcome to Aethlon Medical's Fiscal Year-end March 31, 2026, Earnings Conference Call. My name is Jim Frakes, and I'm the Chief Executive Officer and Chief Financial Officer of Aethlon Medical. At 4:15 p.m. Eastern Time today, Aethlon Medical released financial results for its fiscal year ended March 31, 2026.
If you have not seen or received Aethlon Medical's earnings release, please visit the Investors page at www.aethlonmedical.com to view it. Following this introduction and the reading of the company's forward
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
